The Claim
In adults with type 2 diabetes and preserved kidney function (eGFR ≥60 mL/min/1.73 m²), once-weekly exenatide is associated with nominal reductions in major adverse cardiovascular events, all-cause mortality, and cardiovascular death; however, these associations are not statistically significant in interaction tests and are derived from unadjusted analyses.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with type 2 diabetes and healthy kidneys, taking a weekly exenatide shot might slightly lower the risk of heart problems or dying, but the evidence isn't strong and hasn't been fully checked for other factors.
See the scientific wording
In adults with type 2 diabetes and preserved kidney function (eGFR ≥60 mL/min/1.73 m²), once-weekly exenatide is associated with nominal reductions in major adverse cardiovascular events, all-cause mortality, and cardiovascular death, but these findings are not supported by significant interaction tests and are based on unadjusted analyses.
What the research says
1 studyThe study looked at a diabetes drug called once-weekly exenatide and found it may slightly lower heart risks in people with healthy kidneys, but the evidence isn’t strong enough to be sure.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.